“Ozempic Vagina” Is The Latest GLP-1 “Side Effect” To Take The Internet By Storm, So Here’s What It Actually Means
While many are aware of terms like “Ozempic face” and “Ozempic butt,” people are discovering another “side effect” of GLP-1 medications.View Entire Post ›
“I Didn’t Know That Was A Thing”: 31 Unexpected Side Effects Of GLP-1s That Have Nothing To Do With Weight Loss
“I still don’t see ‘me’ in the mirror.”View Entire Post ›
Lilly’s guidance has jumped by $10B as GLP-1 sales keep blowing past expectations
With the commercial business performing so well, Eli Lilly is eyeing earlier business development bets to build out a longer-term pipeline.
GLP-1 drugs may help patients shed regained weight after bariatric surgery
People who regain weight after bariatric surgery may benefit from glucagon-like peptide-1 receptor agonists, commonly called GLP-1 medications, according to a study involving Regenstrief Institute, Indiana University, Purdue University and University of Florida researchers. The study found that patients prescribed these medications lost more of their regained weight over six and 12 months than comparable patients who did not use them.
Lilly can’t stop, won’t stop as revenue climbs 39% thanks to GLP-1 bestsellers
Eli Lilly’s shares rose 4% in early morning trading after reporting revenue of $24.4 billion, well past consensus estimates.
Lilly triple G retatrutide beats Ozempic in head-to-head trial
Thursday, October 29 – Already tagged with a potential “best-in-class” description by industry analysts on the back of positive phase III data unveiled earlier this year, Eli Lilly and Co.’s retatrutide turned up another win, this time besting Novo Nordisk A/S’ GLP-1 blockbuster, Ozempic (semaglutide), on A1C-lowering and weight loss endpoints in a phase III study in patients with type 2 diabetes.
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
Thursday, October 29 – Eli Lilly announced that its investigational drug retatrutide was more effective at lowering blood sugar and cutting weight than Novo Nordisk’s Ozempic in a large diabetes study.
Lilly’s retatrutide trounces Novo’s Ozempic in diabetes, weight loss
Thursday, October 29 – Eli Lilly’s next-gen weight loss drug retatrutide soundly beat Novo’s approved medicine Ozempic in weight loss and blood sugar reduction, padding the case for a regulatory application that’s expected in the first quarter of 2027.
STAT+: Lilly says ‘triple-G’ drug beat Novo’s Ozempic in diabetes study
Thursday, October 29 – Data add to expectations that the drug will be one of Lilly’s greatest growth drivers.
Courts Take On Lilly GLP-1 Ads, J&J Mesothelioma Trial, More
Wednesday, October 28 – Law360 Healthcare Authority looks at a Novo Nordisk loss in its challenge to Eli Lilly’s GLP-1 advertising, an Ohio verdict in wrongful death litigation over Johnson & Johnson’s talc baby powder and other legal news from the past week.